{"id":391683,"date":"2020-12-02T08:35:08","date_gmt":"2020-12-02T13:35:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=391683"},"modified":"2020-12-02T08:35:08","modified_gmt":"2020-12-02T13:35:08","slug":"allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/","title":{"rendered":"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>Webinar Scheduled for 11:00 AM PT\/2:00 PM ET<\/li>\n<\/ul>\n<p>SOUTH SAN FRANCISCO, Calif., Dec.  02, 2020  (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed\/refractory multiple myeloma on December 5, 2020 via a live webinar at 11:00 AM Pacific Time\/2:00 PM Eastern Time.<\/p>\n<p>Webinar Presenters:<\/p>\n<ul type=\"disc\">\n<li>David Chang, M.D., Ph.D. \u2013 President, Chief Executive Officer and Co-Founder of Allogene<\/li>\n<li>Rafael Amado, M.D. \u2013 Executive Vice President of Research &amp; Development and Chief Medical Officer of Allogene<\/li>\n<li>Parameswaran Hari, M.D., MRCP \u2013 Chief of the Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin<\/li>\n<\/ul>\n<p>\n        <strong>Webinar<\/strong><br \/>\n        <br \/>Please register for the webinar on the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HdKyaeyeCQq4mafYq-0X7QLeOgsnjZSx1ULcLdMvGg4w1U06Ophw3YwI6wc1HHG3MEhhvhLNma1LeYGxTqKguA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.allogene.com<\/a> under the Investors tab in the News and Events section (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3LgsE7ltwFX-NsC7nHO58OuEcK4-ncm0ZmifcWIs5a_zqeewJq-IJcGroB_rMoKG7pgcU6P8o3w_FPXAlcBIw7zavAiGoNtXn0QEny4OpLd9KUQ7mO1Gc14owaMg5FS9\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/ir.allogene.com\/events<\/a>) or by clicking the following <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BRFXUePNu8kAEKb_4R3mSeNUyZs9VFZgcv_mQPG5EHZh5489TzTjh_FjABsJuIi3C7qw1NHgrnaScugAZP610hTP34fe8eqCfjCm_WO9LYoa74rOdwXuVv7jA2mO7f1X_1sKY3ZU47ID4PBhx0CogN3YAXP7fVhZRl2wVGfmFn_pfRDo2tItXslFRkdeEcp7\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">link<\/a> directly.<\/p>\n<p>The webinar will be available as a live event only and the materials presented will be available on the Allogene website prior to the start of the event.<\/p>\n<p>\n        <strong>About Allogene Therapeutics<\/strong><br \/>\n        <br \/>Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T\u2122) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of \u201coff-the-shelf\u201d CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as &#8220;predicts,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;proposed,&#8221; &#8220;continue,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop AlloCAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene\u2019s expectations and actual results as discussed in greater detail in Allogene\u2019s filings with the Securities and Exchange Commission (SEC), including without limitation in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>AlloCAR T\u2122 is a trademark of Allogene Therapeutics, Inc.<\/p>\n<p>\n        <strong>Allogene Media\/Investor Contact:<\/strong><br \/>\n        <br \/>Christine Cassiano<br \/>Chief Communications Officer<br \/>(714) 552-0326<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=--L6gcEYq53xlN37Uy8-BHkJx2Z5DSpWGi76KcuB2lv1h856GLymY2SvWrHPerf1QdwHZlp_-Y6jqaK2h8KKu8EmoQDE4A5CGkoCUGQ04bP8VCyii2pjCYmckS57tPGb\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Christine.Cassiano@allogene.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f9b66cc0-ea8c-4d86-b969-ce7ad45973c5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Webinar Scheduled for 11:00 AM PT\/2:00 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed\/refractory multiple myeloma on December 5, 2020 via a live webinar at 11:00 AM Pacific Time\/2:00 PM Eastern Time. Webinar Presenters: David Chang, M.D., Ph.D. \u2013 President, Chief Executive Officer and Co-Founder of Allogene Rafael Amado, M.D. \u2013 Executive Vice President of Research &amp; Development and Chief Medical Officer of Allogene Parameswaran Hari, M.D., MRCP \u2013 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-391683","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webinar Scheduled for 11:00 AM PT\/2:00 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed\/refractory multiple myeloma on December 5, 2020 via a live webinar at 11:00 AM Pacific Time\/2:00 PM Eastern Time. Webinar Presenters: David Chang, M.D., Ph.D. \u2013 President, Chief Executive Officer and Co-Founder of Allogene Rafael Amado, M.D. \u2013 Executive Vice President of Research &amp; Development and Chief Medical Officer of Allogene Parameswaran Hari, M.D., MRCP \u2013 &hellip; Continue reading &quot;Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-02T13:35:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020\",\"datePublished\":\"2020-12-02T13:35:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/\"},\"wordCount\":507,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/\",\"name\":\"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=\",\"datePublished\":\"2020-12-02T13:35:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/","og_locale":"en_US","og_type":"article","og_title":"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020 - Market Newsdesk","og_description":"Webinar Scheduled for 11:00 AM PT\/2:00 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed\/refractory multiple myeloma on December 5, 2020 via a live webinar at 11:00 AM Pacific Time\/2:00 PM Eastern Time. Webinar Presenters: David Chang, M.D., Ph.D. \u2013 President, Chief Executive Officer and Co-Founder of Allogene Rafael Amado, M.D. \u2013 Executive Vice President of Research &amp; Development and Chief Medical Officer of Allogene Parameswaran Hari, M.D., MRCP \u2013 &hellip; Continue reading \"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-02T13:35:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020","datePublished":"2020-12-02T13:35:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/"},"wordCount":507,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/","name":"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=","datePublished":"2020-12-02T13:35:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTA4MyMzODUxNzkyIzIxMjQyNDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on-december-5-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=391683"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391683\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=391683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=391683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=391683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}